A phase II trial with safety run-in of neoadjuvant therapy with an aromatase inhibitor in combination with durvalumab (MEDI4736) in postmenopausal patients with hormone-receptor-positive (HR plus ) breast cancer

Hung T. Khong, Dawn N. Goodridge, Nazanin Khakpour, M. Catherine Lee, Christine Laronga,Avan J. Armaghani, Aixa E. Soyano-Muller, Hyo Han, Hatem Soliman, Ricardo Costa, Loretta Loftus, Susan J. Hoover, John V. Kiluk, Zena Jameel, Brian J. Czerniecki

CANCER RESEARCH（2021）

引用 0|浏览6